Results 31 to 40 of about 181,126 (162)

The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy

Sultan Qaboos University Medical Journal, 2019
Programmed death ligand 1 (PD-L1) is an inhibitory molecule expressed by cancer cells to supress T-cell activity and escape anti-tumour immunity. The role of PD-L1 in cancer has been studied extensively as it is considered an important immune checkpoint ...
Malika Al-Dughaishi, Asem Shalaby, Khawla Al-Ribkhi, Ammar Boudaka, Mohamed-Rachid Boulassel, Jumana Saleh   +5 more
doaj   +1 more source

The prevalence of TNFα-induced necrosis over apoptosis is determined by TAK1-RIP1 interplay.

PLoS ONE, 2011
Death receptor-induced programmed necrosis is regarded as a secondary death mechanism dominating only in cells that cannot properly induce caspase-dependent apoptosis.
Seda Çöl Arslan, Claus Scheidereit
doaj   +1 more source

The Molecular Links between Cell Death and Inflammasome

Cells, 2019
Programmed cell death pathways and inflammasome activation pathways can be genetically and functionally separated. Inflammasomes are specialized protein complexes that process pro-inflammatory cytokines, interleukin-1β (IL-1β), and IL-18 to ...
Kwang-Ho Lee, Tae-Bong Kang
doaj   +1 more source

Research Progress of Anti-PD-1/PD-L1 Therapy for Non-small Cell Lung Cancer 
with EGFR Mutation

Chinese Journal of Lung Cancer, 2022
The use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the first line treatment for EGFR-mutant advanced non-small cell lung cancer (NSCLC), but drug resistance will be acquired within 1-2 years, and the following treatment
Yue ZHU, Zhaoxia DAI
doaj   +1 more source

Senescent cells re‐engineered to express soluble programmed death receptor‐1 for inhibiting programmed death receptor‐1/programmed death ligand‐1 as a vaccination approach against breast cancer [PDF]

Cancer Science, 2018
Various types of vaccines have been proposed as approaches for prevention or delay of the onset of cancer by boosting the endogenous immune system. We previously developed a senescent‐cell‐based vaccine, induced by radiation and veliparib, as a preventive and therapeutic tool against triple‐negative breast cancer. However, the programmed death receptor‐
Zehong Chen, Kang Hu, Lieting Feng, Ruxiong Su, Nan Lai, Zike Yang, Shijun Kang   +6 more
openaire   +2 more sources

Microbiome Modulation in Lung Cancer Immunotherapy: Unveiling the Role of Respiratory and Gut Microbiota in the PD-1/PD-L1 Response

Frontiers in Bioscience-Landmark
Lung cancer, the leading cause of cancer-related mortality worldwide, poses considerable therapeutic challenges due to the varied responses to programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors.
Yuanyuan Xu, Yixing Tao, Hanbo Pan, Zhongjie Wang, Hui Wang, Qingquan Luo   +5 more
doaj   +1 more source

Predictive biomarkers of response to immune checkpoint inhibitors [PDF]

Farmacia Hospitalaria, 2020
Objective: The present paper provides a literature review aimed at identifying the tumor-dependent factors capable of influencing a subject’s response to immune checkpoint inhibitors, with a special emphasis on those that may act as predictive ...
María Sacramento Díaz-Carrasco, Eva González-Haba, Juana Inés García-Soler, Alberto Espuny-Miró   +3 more
doaj   +1 more source

PD-L1 and CD8+ T cell evaluation in breast cancers and their correlation with clinicopathological parameters

Journal of the Pakistan Medical Association
Objective: To determine the immunohistochemical expression of Programmed cell Death Ligand 1 and intratumoural cluster of differentiation-8-positive T lymphocyte count in primary breast cancer cases, and to ascertain their association with different ...
Sayher Kazmi, Sumayyah Shawana, Nighat Jamal   +2 more
doaj   +1 more source

Efficacy of salvage therapies for advanced acral melanoma after anti-PD-1 monotherapy failure: a multicenter retrospective study of 108 Japanese patients

Frontiers in Medicine, 2023
BackgroundAnti-programmed cell death protein 1 (PD-1) monotherapy is one of the standard systemic therapies for advanced melanoma; however, the efficacy of salvage systemic therapies after PD-1 monotherapy failure (PD-1 MF), particularly in acral ...
Tatsuhiko Mori, Kenjiro Namikawa, Naoya Yamazaki, Yukiko Kiniwa, Osamu Yamasaki, Shusuke Yoshikawa, Takashi Inozume, Hiroshi Kato, Yasuo Nakai, Satoshi Fukushima, Tatsuya Takenouchi, Takeo Maekawa, Shigeto Matsushita, Atsushi Otsuka, Atsushi Otsuka, Motoo Nomura, Natsuki Baba, Taiki Isei, Shintaro Saito, Noriki Fujimoto, Ryo Tanaka, Takahide Kaneko, Yutaka Kuwatsuka, Taisuke Matsuya, Kotaro Nagase, Masazumi Onishi, Takehiro Onuma, Yasuhiro Nakamura   +27 more
doaj   +1 more source

Research Progress on the Mechanism and Clinical Data of Cereblon 
in Reversing the Resistance of Lung Cancer to PD-1 Antibody by T cells

Chinese Journal of Lung Cancer, 2021
Programmed cell death receptor 1 (PD-1) is a membrance-spanning protein mostly expressed in the T cell, and combines with programmed cell death ligand 1 (PD-L1) in the targeting cell.
Jingjing GUO, Di MU, Ying HAN
doaj   +1 more source